Currently, there are 54.95M common shares owned by the public and among those 52.96M shares have been available to trade.
The company’s stock has a 5-day price change of 0.75% and 18.78% over the past three months. GKOS shares are trading 68.44% year to date (YTD), with the 12-month market performance up to 76.85% higher. It has a 12-month low price of $59.22 and touched a high of $136.36 over the same period. GKOS has an average intraday trading volume of 549.85K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 7.01%, 10.05%, and 35.96% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Glaukos Corporation (NYSE: GKOS) shares accounts for 100.40% of the company’s 54.95M shares outstanding.
It has a market capitalization of $7.36B and a beta (3y monthly) value of 1.02. The earnings-per-share (ttm) stands at -$3.20. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.09% over the week and 2.90% over the month.
Earnings per share for the fiscal year are expected to increase by 7.45%, and 35.85% over the next financial year. EPS should grow at an annualized rate of 8.00% over the next five years, compared to -49.95% over the past 5-year period.
Looking at the support for the GKOS, a number of firms have released research notes about the stock. Citigroup stated their Neutral rating for the stock in a research note on July 10, 2024, with the firm’s price target at $132. Jefferies coverage for the Glaukos Corporation (GKOS) stock in a research note released on May 06, 2024 offered a Buy rating with a price target of $125. JP Morgan was of a view on December 21, 2023 that the stock is Overweight, while Morgan Stanley gave the stock Equal-Weight rating on December 04, 2023, issuing a price target of $65. Truist on their part issued Buy rating on November 28, 2023.
